LifeCycle Pharma A/S to Host Conference Call Announcing Interim Report for 1st Quarter 2009

Investor Service Announcement no. 3/2009			

To: NASDAQ OMX Copenhagen          	Hørsholm, Denmark, May 9, 2009



LifeCycle Pharma A/S to Host Conference Call Announcing 
Interim Report for 1st Quarter 2009 - results from January 1 to March 31, 2009

LifeCycle Pharma A/S (OMX: LCP) will announce the Interim Report for 1st
Quarter 2009 on Thursday May 14, 2009. LCP's Executive Management will host an
accompanying conference call to discuss the financial results on Thursday May
14, 2009 at 15:00 CET (Denmark); 14:00 GMT (London), 09:00 AM ET (New York),
06:00 AM PT (San Francisco). 

To access the live conference call, please dial one of the following numbers:
+1 866 966 5335 (US)
+44 2030 032 666 (UK)
+45 8088 8649 (DK)

An audio replay of the conference call will be available on www.lcpharma.com
from Thursday, May 14, 2009 at 18:00 CET (Denmark); 17:00 GMT (London), 12:00
PM ET (New York), 09:00 AM PT (San Francisco), through Friday, June 12, 2009 by
dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code
8403 264#. 


For more information, please contact:
Dr. Jim New                              Peter Schøtt Knudsen
President & Chief Executive Officer or   Head of Investor Relations
Phone: + 45 7033 3300                    Phone: + 45 2055 3817	
Email: JSN@lcpharma.com                  Email: PSK@lcpharma.com				



	
About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide®, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP). 

For further information, please visit www.lcpharma.com.